EUCTR2011-004160-30-DE进行中（未招募）不适用
A multicenter, randomized, active-controlled study to assess the safety, tolerability, and efficacy of FTY720 in patients with acute, noninfectious intermediate, posterior and pan uveitis - Efficacy and Safety of Fingolimod in patients with uveitis
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Active, noninfectious or posterior, intermediate- or pan-uveitis
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusions:
- •1. Vaso-occlusive vasculitis involving the retinal macula
- •2. Behçet’s uveitis
- •3. A history of clinically significant macular edema in either eye within 8 weeks of the screening visit
- •4. Evidence of retinal or sub-retinal fluid on OCT consistent with macular edema of sufficient severity to reduce visual acuity.
- •5. A clinical history of multiple sclerosis (MS)
- •6. Patients receiving Class Ia or Class III antiarrhythmic drugs, beta blockers, calcium channel blockers; those with a low heart rate (HR), history of syncope, sick sinus syndrome, 2nd degree or higher conduction block, ischemic heart disease, or congestive heart failure
- •7. Patients requiring corticosteroid or another systemic immunosuppressive medication for any other disease (e.g., asthma or some other autoimmune disease) that would contraindicate tapering (topical steroids permitted)
研究者
相似试验
进行中（未招募）
1 期
A multi-center study to assess the safety, effectiveness and tolerance of a study drug FTY720 in patients with certain types of the eye disease uveitis (inflammation in the back of the eye).EUCTR2011-004160-30-GBovartis Pharma Service AG
进行中（未招募）
1 期
A study to compare how safe and well tolerated study drug Abelacimab (MAA868) is comapred to another drug called Rivaroxaban in patients with heart condition that causes an irregular and abnormally fast heart rate.MedDRA version: 20.0Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersAtrial FibrillationEUCTR2020-004507-13-CZAnthos Therapeutics1,200
进行中（未招募）
1 期
A study to compare how safe and well tolerated study drug Abelacimab (MAA868) is comapred to another drug called Rivaroxaban in patients with heart condition that causes an irregular and abnormally fast heart rate.MedDRA version: 20.0Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersAtrial FibrillationEUCTR2020-004507-13-HUAnthos Therapeutics1,200
进行中（未招募）
1 期
A study to compare how safe and well tolerated study drug Abelacimab (MAA868) is comapred to another drug called Rivaroxaban in patients with heart condition that causes an irregular and abnormally fast heart rate.MedDRA version: 20.0Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersAtrial FibrillationEUCTR2020-004507-13-PLAnthos Therapeutics1,200
进行中（未招募）
1 期
A study to compare how safe and well tolerated study drug Abelacimab (MAA868) is compared to another drug called Rivaroxaban in patients with heart condition that causes an irregular and abnormally fast heart rateMedDRA version: 20.0Level: PTClassification code: 10003658Term: Atrial fibrillation Class: 100000004849Atrial FibrillationCTIS2023-509066-38-00Anthos Therapeutics Inc.1,200